CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
Key Highlights
- ➤CRISPR Therapeutics appoints Siva Sakhamuri, Ph.D., chief technical officer
- ➤Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience
- ➤Sakhamuri previously led Orna Therapeutics’ CMC and quality organizations
- ➤CRISPR Therapeutics advances gene editing and RNA therapies into late-stage clinical development
Expert Statements
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“Siva has tremendous experience advancing novel therapies across various modalities into the clinic all the way through commercial stage, with expertise spanning biologics, RNA therapeutics and vaccines.”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“It is exciting to have Siva join our leadership team as we advance both our gene editing and RNA therapies into late-stage clinical development.”
Sivakesava (Siva) Sakhamuri, Chief Technical Officer of CRISPR Therapeutics
“CRISPR Therapeutics has built a broad pipeline and strong in-house manufacturing capabilities, and I am excited to join at this stage of the Company’s growth.”
Sivakesava (Siva) Sakhamuri, Chief Technical Officer of CRISPR Therapeutics
“I look forward to working with the talented team to scale our technical operations and manufacturing organization as we work to bring these investigational therapies to patients.”
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery.
“Siva has tremendous experience advancing novel therapies across various modalities into the clinic all the way through commercial stage, with expertise spanning biologics, RNA therapeutics and vaccines,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “It is exciting to have Siva join our leadership team as we advance both our gene editing and RNA therapies into late-stage clinical development.”
Get started
Create a free account to read the full story.